Interleukin-8 in the pathogenesis of primary central nervous system lymphoma in association with HIV infection

Hematology

Volumn 17, Issue 3, 2012, Pages 144-150

  Sasakawa, Atsushi ^a   Hirase, Chikara ^a   Yamaguchi, Terufumi ^a   Morita, Yasuyoshi ^a   Miyatake, Jun ichi ^a   Matsumura, Itaru ^a   Maeda, Yasuhiro ^b  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MINAMI OSAKA GENERAL HOSPITAL   (Japan)

Author keywords

AIDS related lymphoma; CD18 expression; Interleukin 8; PCNSL

Indexed keywords

CD18 ANTIGEN; CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; SIMVASTATIN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIOSARCOMA; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CARCINOGENESIS; CASE REPORT; CELL ADHESION; CELL ASSAY; CELL TRANSFORMATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOBLASTOID CELL LINE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL;

ANTI-HIV AGENTS; ANTIGENS, CD18; CELL ADHESION; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; HERPESVIRUS 4, HUMAN; HIV; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-8; LYMPHOMA, AIDS-RELATED; SIMVASTATIN; ZIDOVUDINE;

EID: 84863112713     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13376952196377     Document Type: Article

References (30)

1. Spano JP, Atlan D, Breau JL, Farge D. AIDS and non-AIDSrelated malignancies: a new vexing challenge in HIV-positive patients, part I: Kaposi's sarcoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma. Eur J Intern Med. 2002;13:170-179.
2. Raez LE, Patel P, Feun L, Restrepo A, Raub WA Jr, Cassileth PA. Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)- related primary central nervous system lymphoma (PCNSL). Crit Rev Oncog. 1998;9:199.
3. Herrlinger U, Schabet M, Bitzer M, Petersen D, Krauseneck P. Primary central nervous system lymphoma: from clinical presentation to diagnosis. J Neurosurg. 2000;92:261-266.
4. Fitzsimmons A, Upchurch K, Batchelor T. Clinical features and diagnosis of primary central nervous system lymphoma. Hematol Oncol Clin North Am. 2005;19:689-703.
5. Anthony IC, Crawford DH, Bell JE. B lymphocytes in the normal brain: contrasts with HIV-associated lymphoid infiltrates and lymphomas. Brain. 2003;126:1058.
6. Alderson L, Fetell MR, Sisti M, Hochberg F, Cohen M, Louis DN. Sentinel lesions of primary CNS lymphoma. J Neurol Neurosurg Psychiatry. 1996;60:102-105.
7. Drillenburg P, Pals ST. Cell adhesion receptors in lymphoma dissemination. Blood. 2000;95:1900-1910.
8. Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT. Expression of B-cell-attracting chemokine 1 (CXCL 13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood. 2003;101: 815-821.
9. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301-314.
10. Masuzawa M, Fujita Y, Hara H, Nishiyama S, et al. Establishment of a human hemangiosarcoma cell line (ISOHAS). Int J Cancer. 1999;81:305-1308.
11. Carrasco YR, Fleire SJ, Cameron T, Dustin ML, Batista FD. LFA-1/ICAM-1 interaction lowers the threshold of B cell activation by facilitating B cell adhesion and synapse formation. Immunity. 2004;20:589-599.
12. Szkodziński J, Romanowski W, Hudzik B, Kaszuba A, Nowakowska-Zajdel E, Szkilnik R, et al. Effect of HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors on the concentration of insulin-like growth factor-1 (IGF-1) in hypercholesterolemic patients. Pharmacol Rep. 2009;61:654-664.
13. Li S, Wang H, Peng B, Zhang M, Zhang D, Hou S, et al. Efalizumab binding to the LFA-1 alphaL I domain blocks ICAM-1 binding via steric hindrance. Proc Natl Acad Sci USA. 2009;106:4349-54.
14. Schramm R, Menger MD, Harder Y, Schmits R, Adam O, Weitz-Schmidt G, et al. Statins inhibit lymphocyte homing to peripheral lymph nodes. Immunology. 2007;120:315-324.
15. Gerstner E, Batchelor T. Primary CNS lymphoma. Expert Rev Anticancer Ther. 2007;7:689-700.
16. Portegies P, Solod L, Cinque P, Chaudhuri A, Begovac J, Everall I, et al. Guidelines for the diagnosis and management of neurological complications of HIV infection. Eur J Neurol. 2004;11: 297-304.
17. Purcet S, Minuesa G, Molina-Arcas M, Erkizia I, Casado FJ, Clotet B, et al. 3′-Azido-2′, 3′-dideoxythymidine (zidovudine) uptake mechanisms in T lymphocytes. Antivir Ther. 2006;11: 803-811.
18. Knowles DM. Etiology and pathogenesis of AIDS-related non- Hodgkin's lymphoma. Hematol Oncol Clin North Am. 2003; 17:785-820.
19. Bashir R, Coakham H, Hochberg F. Expression of LFA-1/ ICAM-1 in CNS lymphomas: possible mechanism for lymphoma homing into the brain. J Neurooncol. 1992;12: 103-110.
20. Katano H, Pesnicak L, Cohen JI. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci USA. 2004;101:4960-4695.
21. Kurokawa M, Ghosh SK, Ramos JC, Mian AM, Toomey NL, Cabral L, et al. Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood. 2005;106:235-240.
22. Diamond C, Taylor TH, Im T, Miradi M, Wallace M, Anton-Culver H. Highly active antiretroviral therapy is associated with improved survival among patients with AIDS-related primary central nervous system non-Hodgkin's lymphoma. Curr HIV Res. 2006;4:375-378.
23. Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS. 2003;17:1787-1793.
24. Rhein P, Mitlohner R, Basso G, Gaipa G, Dworzak MN, Kirschner-Schwabe R, et al. CD11b is a therapy resistanceand minimal residual disease-specific marker in precursor Bcell acute lymphoblastic leukemia. Blood. 2010;115:3763-771.
25. Matsumoto T, Mike T, Nelson RP, Trudeau WL, Lockey RF, Yodoi J. Elavated serum level of IL-8 in patients with HIV infection. Clin Exp Immunol. 1993;93:149-151.
26. Cota M, KLeinschmidt A, Ceccherini-Silberstein F, Aloisi F, Mengozzi M, Mantovani A, et al. Upregulated expression of interleukin-8, RAMTES and chemokine receptors in human astrocytic cells infected with HIV-1. J Neurovirol. 2000; 6:75-83.
27. Kedzierska K, Crowe SM. Cytokines and HIV: interactions and clinical implications. Antiviral Chem Chemother. 2001;12: 133-150.
28. Sharma V, Zhang L. Interleukin-8 expression in AIDS-associated lymphoma B-cell lines. Biochem Biophys Res Commun. 2001;282:369-375.
29. Klein SC, Kube D, Abts H, Diehl V, Tesch H. Promotion of IL-8, IL-10, TNFα and TNFb production by EBV infection. Leukemia Res. 1996;20:633-636.
30. Rot A. Endothelial cell binding of NAL-1/IL-8: Role in neutrophil emigration. Immunol Today. 1992;13:291-294.